Navigation Links
Bio-Solutions Corp. Expanding in Booming Diabetes Market
Date:8/29/2013

CORAL SPRINGS, Florida, August 29, 2013 /PRNewswire/ --

On Wednesday, Bio-Solutions Corp. (OTCQB: BISU) announced their Direct Response Infomercial and Marketing Campaign for its flagship product, Type2Defense. Over 30 million people suffer from Type 2 diabetes in the United States, according to seeking alpha. Additionally, it's forecasted that nearly 30 percent of the U.S.'s population will have diabetes by 2050, with most of that percentage facing Type 2.

United Healthcare predicts spending on diabetes will grow significantly over the next 10 years, estimating that the country will spend around $3.4 trillion on the disease. The total cost of diagnosed diabetes in 2012 was $245 billion, as stated by the American Diabetes Association. This was a 41 percent increase from 2007, when costs reached $174 billion.

Bio-Solutions' Type2 Defense is a powder blend of natural ingredients that has been developed to help support healthy blood glucose levels in health-conscious individuals and those diagnosed with Type II Diabetes. With the launch of Type 2 Defense's new infomercial and marketing campaign, BISU takes a significant step in their expansion across the U.S.

The partnership with Direct Response Marketing isn't the first step Bio-Solutions has taken in effort to expand, as they also recently announced they have begun a campaign on Lockerdome.com. Lockerdome.com is the premier destination on the internet for both professional and amateur athletes, with monthly traffic in excess of 14 million visitors. The Company's campaign on the website will allow young athletes with diabetes to interact with pro athletes also suffering from the disease.

For more recent news for BISU, please click on the following links:

http://finance.yahoo.com/news/bio-solutions-corporation-announces-campaign-113000206.html

http://finance.yahoo.com/news/bio-solutions-corporation-launches-type2defense-150000680.html

About Bio-Solutions Corp.

Bio-Solutions Corp. markets new and very effective organic products; our lead product is Type2 Defense™. Type2Defense™ a Diabetic Supplement Drink. Type2Defense™ is a new dietary supplement that has been developed to help support healthy blood glucose levels in health-conscious individuals and those diagnosed with Type 2 Diabetes. The Product's goal is to provide a safe and natural supplement that will assist in the stabilization of healthy glucose levels along with providing strong antioxidants. Consumers can find more information about the company and its products by going to http://www.BioSolutionsCorp.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements which address actual results could differ materially from those expressed or implied in forward-looking statements. These statements are made on the basis of management's views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as management "believes", "expects", "anticipates", "foresees", "forecasts", "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward looking statements. Management cautions that the ability to attract clients and generate business may be affected by a decline in the Company's financial ratings, the competitive environment, the Company's ability to raise sufficient capital to meet the collateral requirements associated with its current business and to fund the Company's continuing operations and changes in market conditions.

Investor Relations Contact
William Gallagher
+1-210-218-4475
info@biosolutionscorp.com

Contact:
FN Media Group, LLC
+1-954-345-0611
editor@financialnewsmedia.com



'/>"/>
SOURCE FN Media Group LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
2. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
3. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
4. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
5. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
6. Millennium Surgical Corp. Announces Sales Figures, Growth
7. Millennium Surgical Corp. Develops Online Sterilization Resource Center
8. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
9. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
11. Online Pharmacy Domain Policy Changes Announced by ICANN Registrar Internet.bs Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services ... The announcement was made by Bill Monast , ... Hartley and Nathan Feltman , executives with ... Healthcare Services, LLC. This acquisition helps ... provider of technology enabled durable medical equipment (DME) solutions ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device company that ... pain, today reported financial results for the three months and ... Accomplishment & Highlights: Achieved revenue of $228.5 ... as reported, over the prior year U.S. revenue ... the prior year International revenue of $55.2 ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Curemark, LLC announced ... and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at ... already enrolling children across the United States. , “There are currently no approved ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered ... exercise regime, the author was able to successfully recover. In “ Origin & Insertion ... for various sources on the principals of massage, anatomy , trigger points ...
Breaking Medicine News(10 mins):